Abstract
Primary vitreoretinal lymphoma (PVRL) is a rare malignancy classified as a diffuse large B-cell lymphoma and is frequently found in conjunction with primary central nervous system lymphoma. Optimal treatment for PVRL is not defined given its relatively low incidence but often requires a combination of systemic and/or intravitreal methotrexate and rituximab. Survival rate for this disease is low, with high rates of recurrence despite treatment. The authors describe successful treatment of vitreoretinal lymphoma in a patient with recurrent disease with the use of the systemic agent ibrutinib. [Ophthalmic Surg Lasers Imaging Retina. 2021;52:227-230.].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
